Hims & Hers Health (NYSE:HIMS) Trading 6.7% Higher

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) rose 6.7% on Thursday . The company traded as high as $16.32 and last traded at $16.29. Approximately 3,240,439 shares traded hands during trading, a decline of 58% from the average daily volume of 7,757,520 shares. The stock had previously closed at $15.27.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Citigroup lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and increased their target price for the stock from $16.00 to $20.00 in a report on Wednesday, May 22nd. Jefferies Financial Group upped their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Bank of America raised their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.29.

Hims & Hers Health Stock Up 4.9 %

The company’s 50 day moving average price is $17.97 and its two-hundred day moving average price is $16.92. The firm has a market cap of $3.44 billion, a PE ratio of -1,606.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same quarter last year, the firm earned ($0.03) earnings per share. The firm’s quarterly revenue was up 51.8% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 45,755 shares of the company’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $22.97, for a total value of $1,050,992.35. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $769,540.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,609 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40. Following the completion of the sale, the chief financial officer now directly owns 181,469 shares of the company’s stock, valued at $2,649,447.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 45,755 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $22.97, for a total transaction of $1,050,992.35. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $769,540.94. The disclosure for this sale can be found here. Insiders have sold 753,292 shares of company stock valued at $13,557,329 in the last quarter. 17.71% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently made changes to their positions in the business. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health during the 4th quarter valued at approximately $86,836,000. Renaissance Technologies LLC lifted its position in Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after acquiring an additional 3,205,108 shares during the period. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the period. M&G Plc purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $8,232,000. Finally, State of Michigan Retirement System increased its holdings in shares of Hims & Hers Health by 177.8% in the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock valued at $10,095,000 after purchasing an additional 320,000 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.